Dr. Laurence Tokaz, M.D.
What this data tells you about Dr. Tokaz
Dr. Laurence Tokaz is a medical oncology specialist in Austin, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Tokaz performed 60,248 Medicare services across 2,501 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tokaz received a total of $27,309 from 14 pharmaceutical and/or device companies across 47 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tokaz is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 12,750 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 8,100 | $43 | $136 |
| Iron sucrose injection (Venofer) | 7,100 | $0 | $2 |
| Nivolumab injection (Opdivo) | 7,100 | $21 | $76 |
| Anti-nausea injection (fosaprepitant) | 6,600 | $0 | $5 |
| Paclitaxel chemotherapy injection | 4,680 | $0 | $8 |
| Denosumab injection (Prolia/Xgeva) | 2,160 | $18 | $66 |
| Dexamethasone injection (steroid) | 1,899 | $0 | $1 |
| Injection, bortezomib, 0.1 mg | 1,330 | $4 | $116 |
| Immune globulin infusion (Octagam) | 1,240 | $33 | $234 |
| Anti-nausea injection (Aloxi/palonosetron) | 600 | $1 | $114 |
| Injection, fluorouracil, 500 mg | 597 | $2 | $13 |
| Blood draw (venipuncture) | 486 | $8 | $20 |
| Complete blood count (CBC) with differential | 410 | $8 | $36 |
| Comprehensive metabolic blood panel | 407 | $10 | $64 |
| Injection, potassium chloride, per 2 meq | 385 | $0 | $1 |
| Immunoglobulin level test | 357 | $9 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 308 | $24 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 307 | $107 | $707 |
| Injection of additional new drug or substance into vein | 257 | $13 | $108 |
| Office visit, established patient (30-39 min) | 242 | $88 | $368 |
| Injection, carboplatin, 50 mg | 217 | $2 | $300 |
| Lactate dehydrogenase (enzyme) level | 178 | $6 | $31 |
| Infusion, normal saline solution , 1000 cc | 174 | $2 | $19 |
| Injection, magnesium sulfate, per 500 mg | 156 | $1 | $6 |
| Administration of chemotherapy into vein, each additional hour | 124 | $23 | $161 |
| Infusion into a vein for hydration, each additional hour | 110 | $10 | $75 |
| Office visit, established patient, complex (40-54 min) | 107 | $137 | $496 |
| Measurement of immunoglobulin light chains | 104 | $17 | $60 |
| Injection, zoledronic acid, 1 mg | 97 | $6 | $431 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 96 | $50 | $313 |
| Carcinoembryonic antigen (cea) protein level | 80 | $18 | $99 |
| Drug injection, under skin or into muscle | 80 | $11 | $96 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 80 | $60 | $211 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 79 | $16 | $100 |
| Administration of additional new drug or substance into vein, 1 hour or less | 73 | $53 | $344 |
| Injection, diphenhydramine hcl, up to 50 mg | 73 | $1 | $7 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 72 | $20 | $128 |
| Hospital follow-up visit, moderate complexity | 64 | $60 | $247 |
| Infusion into a vein for hydration, 31-60 minutes | 59 | $26 | $256 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 59 | $316 | $1,722 |
| Microscopic examination for white blood cells with manual cell count | 57 | $4 | $22 |
| Complete blood count (CBC), automated | 57 | $6 | $34 |
| Reticulated (young) platelet measurement | 56 | $35 | $143 |
| Iron level test | 54 | $6 | $27 |
| Iron binding capacity test | 54 | $9 | $35 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 54 | $136 | $500 |
| Ferritin level test (iron stores) | 53 | $13 | $60 |
| Administration of additional new drug or substance into vein using push technique | 53 | $46 | $289 |
| Unclassified drugs | 52 | $1 | $9 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 52 | $135 | $3,675 |
| Injection of drug or substance into vein | 42 | $29 | $247 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 37 | $16 | $94 |
| Hospital follow-up visit, high complexity | 37 | $93 | $357 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 28 | $27 | $145 |
| Beta-2 microglobulin (protein) level | 27 | $16 | $96 |
| Protein measurement, serum | 20 | $11 | $99 |
| Immunologic analysis technique on serum | 20 | $29 | $108 |
| Immunologic analysis technique on serum (immunofixation) | 20 | $22 | $160 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 18 | $91 | $657 |
| Thyroid stimulating hormone (TSH) test | 17 | $16 | $80 |
| Drawing of blood for a medical problem | 17 | $69 | $264 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 14 | $1,228 | $4,802 |
| Office visit, established patient (20-29 min) | 12 | $43 | $250 |
Industry Payment Transparency
Open Payments through 2023 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2023)
Associated products mentioned in payments ›
The majority of payments (71%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2023 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Tokaz is a mixed practice specialist, with above-average Medicare volume (top 17% in TX), with speaking/promotional industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Tokaz experienced with iron infusion (feraheme)?
Does Dr. Tokaz receive payments from pharmaceutical companies?
How do Dr. Tokaz's costs compare to other medical oncologists in Austin?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology